These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16555549)

  • 1. Does survival increase in metastatic breast cancer with recently available anticancer drugs?
    Abrial C; Leheurteur M; Cabrespine A; Mouret-Reynier MA; Durando X; Ferriere JP; Kwiatkowski F; Penault-Llorca F; Cure H; Chollet P
    Oncol Res; 2006; 15(9):431-9. PubMed ID: 16555549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of aromatase inhibitors in the treatment of metastatic breast cancer.
    Mouridsen H; Gershanovich M
    Semin Oncol; 2003 Aug; 30(4 Suppl 14):33-45. PubMed ID: 14513435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should aromatase inhibitors replace tamoxifen?
    Drug Ther Bull; 2003 Aug; 41(8):57-9. PubMed ID: 12966738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT; Robert NJ
    MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
    Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J
    Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
    Hamilton A; Piccart M
    Ann Oncol; 1999 Apr; 10(4):377-84. PubMed ID: 10370778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitors in advanced breast cancer.
    Mouridsen HT
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):3-8. PubMed ID: 15719595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current developments in hormonal therapy of breast cancer.
    Buzdar AU
    Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S4-5. PubMed ID: 15347432
    [No Abstract]   [Full Text] [Related]  

  • 12. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
    Messori A; Cattel F; Trippoli S; Vaiani M
    Anticancer Drugs; 2000 Oct; 11(9):701-6. PubMed ID: 11129731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C
    Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
    Grana G
    J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
    Allred DC; Baum M; Buzdar AU; Carlson RW; Dowsett M; Elledge RM; Gradishar WJ; Grana G; Howell A; Mamounas EP
    Breast J; 2003; 9(3):213-22. PubMed ID: 12752630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
    Brodie AH; Mouridsen HT
    Am J Clin Oncol; 2003 Aug; 26(4):S17-26. PubMed ID: 12902873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
    Prescrire Int; 2005 Jun; 14(77):108-10. PubMed ID: 15984106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.